BioNTech SE (BNTX) has announced initial results from its AHEAD-MERIT Phase 2/3 trial, evaluating its mRNA cancer immunotherapy BNT113 in combination with pembrolizumab for HPV16-positive head and neck cancer.~br~ The trial aims to improve progression-free and overall survival rates, addressing the lack of approved HPV-targeted treatments.~br~

MRNA, BNTX and NVAX shares rally after reports of a planned NIH-backed initiative to accelerate personalized cancer vaccines and expand research funding.

BioNTech SE Sponsored ADR (NASDAQ: BNTX - Get Free Report) CEO Ugur Sahin sold 36,209 shares of the company's stock in a transaction that occurred on Friday, October 9th. The shares were sold at an average price of $95.37, for a total value of $3,453,252.33. Following the transaction, the chief executive officer directly owned 36,209 shares

BioNTech SE Sponsored ADR (NASDAQ: BNTX - Get Free Report) CEO Ugur Sahin sold 27,000 shares of the company's stock in a transaction that occurred on Thursday, October 8th. The shares were sold at an average price of $92.31, for a total value of $2,492,370.00. Following the completion of the transaction, the chief executive officer owned

What happened BioNTech SE (NASDAQ: BNTX) said Chief Executive Officer and 10% owner Ugur Sahin sold 63,209 ordinary shares on 2026-10-08 and 2026-10-09. He sold 27,000 shares at $92.31 on 2026-10-08 and 36,209 shares at $95.37 on 2026-10-09, for about $5.95 million. The Form 4 says the trades were made under a Rule 10b5-1 trading